Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MGTX
MGTX logo

MGTX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MGTX News

MeiraGTx Q1 Earnings Miss Expectations

May 14 2026seekingalpha

MeiraGTx Prices $100M Equity Offering to Acquire Gene Therapy bota-vec

Apr 16 2026seekingalpha

MeiraGTx Acquires bota-vec from J&J for XLRP Treatment

Apr 16 2026Newsfilter

MeiraGTx Shares Surge 17% to 52-Week High Ahead of Gene Therapy Data Presentation

Apr 14 2026seekingalpha

MeiraGTx Presents 3-Year Data from AQUAx Clinical Study

Apr 14 2026Newsfilter

MeiraGTx Stock Rises After Financial Results Announcement

Mar 26 2026NASDAQ.COM

MeiraGTx Receives FDA Breakthrough Therapy Designation for AAV2-hAQP1

Mar 26 2026Newsfilter

Strategic Shift in Biotech Dealmaking

Feb 17 2026Globenewswire

MGTX Events

05/14 08:30
MeiraGTx Reports Q1 Revenue of $293,000
Reports Q1 revenue $293,000 vs. $1.93M last year. "Our achievements in the first few months of 2026 have materially strengthened MeiraGTx - we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years," said Alexandria Forbes, president and chief executive officer of MeiraGTx. "The compelling three-year durability data from our AAV2-hAQP1 Phase 1 study continue to demonstrate disease-modifying benefit following a simple one-time treatment of patients with moderate to severe persistent radiation-induced xerostomia, an otherwise debilitating life-long condition. The recent receipt of Breakthrough Therapy Designation for this program reinforces the strength of the data and the potential for an expedited development and regulatory pathway."
05/12 16:20
Major Averages Finish Mixed as Semiconductor Stocks Pull Back
The major averages had a mixed finish as semiconductor stocks pulled back following a massive multi-week run. AI-driven enthusiasm pushed the S&P 500 and Nasdaq to fresh records yesterday, but investors are now confronting a harder macro backdrop than previously anticipated. Meanwhile, crude is back above $100 as hopes for a durable U.S.-Iran ceasefire continue to deteriorate, with President Trump describing negotiations as being "on life support." Of note, the Iranian Fars news service reportedly said that Iran will not join the next round of U.S. talks without five preconditions being met.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:eBay'sboard rejected GameStop'sUnder Armourreported mostly in-line Q4 results andActivist investor Nelson Peltz's Trian Fund Management is seeking investor backing for a bid to take Wendy'sprivate,BuzzFeedannounced a proposed majority investment byFDA Commissioner Marty Makary has, according to multiple media reports citing administration officials2. WALL STREET CALLS:Lowe'sto Buy at CitiAutodeskat Buy from Neutral at BofARothschildToaston risk from DoorDashU.S. rolloutZoomInfoto Underweight at Piper Sandler and to Neutral-equivalent ratings and several other firmsWall Streetof drone-maker Aevexafter its recent IPO3. AROUND THE WEB:Microsofthas already earned back more than double the capital it invested in OpenAI in terms of new revenue from services related to OpenAI, The Information reportsGoogleand Elon Musk's SpaceX are in talks for a rocket launch deal amid efforts to put orbital data centers in space, WSJ saysAlphabet'sYouTube is looking to connect creators with sponsors to secure funding for shows before they launch, NY Times reportsSoftBankis partnering with South Korea's Cosmos Lab and DeltaX to mass produce next-gen data center batteries in Sakai, Japan at a scale of 1 GWh/year from FY27, Bloomberg reportsBoeing'ssuccess hinges on its successor to the 737, Bloomberg says4. MOVERS:Zebra Technologiesrose after providing areport for Q1SI-Bonewas higher after also providing areport for Q1Gitlabfell after announcing aZoomInfowas lower afterand reiterating its FY26 outlookGoProdeclined after reportingand withdrawing its FY26 guidance5. EARNINGS/GUIDANCE:Sea LimitedreportedBayerprovided areport for Q1Qnity Electronicsalso provided areport for Q1Tencent Musicreported ain Q1 earningsHims & Hers Healthprovidedbut raised its FY26 revenue guidanceINDEXES:The Dow rose 56.09, or 0.11%, to 49,760.56, the Nasdaq lost 185.92, or 0.71%, to 26,088.20, and the S&P 500 declined 11.88, or 0.16%, to 7,400.96.
05/12 14:00
FDA Commissioner Makary Resigns Over E-Cigarette Concerns
Dr. Marty Makary, the commissioner of the Food and Drug Administration, resigned on Tuesday, according to multiple media reports citing administration officials. Makary ultimately resigned over concerns about the administration's decision to authorize fruit-flavored e-cigarettes, which he opposed, four people familiar with the matter told The New York Times. Kyle Diamantas, the F.D.A.'s top food regulator, was named the acting commissioner, according to The Times and Politico, which was first to report of Makary's resignation. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks that could be impacted by the news include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).
05/12 10:50
Trump Plans to Reduce Beef Import Tariffs
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.BEEF IMPORTS:The Trump administration is planning to temporarily reduce tariffs on beef imports as soon as Monday, opening the way to import more beef from overseas as part of a broader effort to address record-high beef prices, people familiar with the matter told's Patrick Thomas and Gavin Bade. Publicly traded meat producers include Hormel Foods, JBS, Pilgrim's Prideand Tyson Foods.FDA CHIEF:President Trump has approved a plan to fire Food and Drug Administration Commissioner Marty Makary, Kristin Brown and Ed O'Keefe of CBS News, citing two sources. The timing of his potential termination remains unknown, CBS adds. Similar reports of Makary's firing emerged on Friday. Biotech stocks that could be impacted by the news include Moderna, Sarepta, Xencor, PTC Therapeutics, Biohaven, Edgewise Therapeutics, Design Therapeutics, Ultragenyx, Dyne Therapeutics, Wave Life Sciences, MeiraGTx, uniQure, Regenxbio, Novavaxand Lexeo Therapeutics.FERTILITY BENEFITS:The U.S. departments of Labor, Health and Human Services, and Treasury last night announced a proposed rule that would create a new category of limited excepted benefits to further expand the ability of employers to offer fertility benefits. The agencies stated, "This proposal addresses employers' sparse coverage of fertility-related treatments for the American worker and increases benefit options by easing statutory and regulatory burdens to make IVF and other fertility treatments more affordable. Though most workers of reproductive age receive healthcare coverage through their jobs, the majority do not have robust fertility coverage." The proposed rule would establish a new category of limited excepted benefits. Excepted benefits are generally exempt from the market reforms under the Affordable Care Act and certain other federal health care coverage laws. Stocks with exposure to the fertility space include Progynyand INVO Fertility.VACCINE INQUIRY:Health Secretary Robert F. Kennedy Jr. has said little publicly about vaccines in recent months, at the behest of a White House worried that his unpopular stance will hurt Republicans in November's midterm elections. But he has not abandoned his quest for evidence that they are unsafe, The New York Times' Christina Jewett and Sheryl Gay Stolberg. Working behind the scenes, Kennedy is spearheading an intense push, across health agencies under his purview, for government scientists and federal data contractors to examine his long-held theory that vaccines are helping to fuel an epidemic of chronic disease, according to multiple people familiar with the effort. Publicly traded companies that make vaccines and drugs include Moderna, Pfizer, BioNTech, Novavax, AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Roche, and Sanofi.NEW YORK TIMES:In a post on Truth Social, President Donald Trump, "The Failing New York Times, which is one of the worst newspapers anywhere in the World, and is losing subscribers on an hourly basis, is now at it again. Just like they covered my Landslide 2024 Presidential Election Victory inaccurately, and without shame, constantly making major mistakes and incorrect predictions at every path along the way, they are now trying to justify Obama and Biden's expensively botched attempt at fixing the long broken, unsightly, and unsanitary Reflecting Pool that NOW sits majestically between the Washington Monument and the Lincoln Memorial. They squandered at least 55 Million Dollars haplessly trying, with no chance of success, to get the Reflecting Pool to work. Instead, they made it worse, keeping it closed for years, and ending up with a leaking, smelling, ode to both of their failed Administrations. It was an embarrassment to Washington, D.C., and to our Country, itself. Despite the vast sums of money spent, they never got the pool to work, and cosmetically it was a total mess for all to see. Now, along comes "TRUMP," who is asked by many patriots if I can fix it. The answer is a resounding, YES, and for a "tiny" fraction of the cost! I worked with our now strong Department of the Interior and explained to them that we should view this as a highly sophisticated swimming pool, not the leaking, dilapidated facade, joints and all, of a building. Instead of taking 4 years to build, at a cost, granite pavers and all, of 400 Million Dollars, we could construct a far superior Reflecting Pool for 5 or 6 Million Dollars, and could complete the project in 2 weeks rather than 4 years. What a difference in time and money, and for a far superior end result! This is not just a paint job, like lowlife "reporter," David Fahrenthold, of theso inaccurately and maliciously stated, it is a deeply complicated work of smart and beautiful construction. It won't leak, it will shine, and be the pride of Washington D.C. for decades to come. I saved more than 390 Million Dollars, and 4 years of no "mess," and was, of course, given no credit by the biased New York Times. Also, I didn't give out the contract, "Interior" did, to a contractor I did not know, and have never used before. Thank you for your attention to this matter!"

MGTX Monitor News

No data

No data

MGTX Earnings Analysis

No Data

No Data

People Also Watch